Nerivio For
Veterans





Did you know?
Veterans are more likely to experience migraine than civilians[1]
Veterans returning home from Iraq and Afghanistan have two to four times the incidence of migraine as compared to the general population [2]
How to get the Nerivio REN wearable from your VA Healthcare Provider
*If not enrolled in the VA system contact by visiting www.va.gov/healthbenefits/enroll or by calling 1-877-222-VETS (1-877-222-8387)
Set an appointment with your VA primary care provider

Speak to your VA primary care provider to see if Nerivio is right for you


Your Nerivio device will be available either at your VA or mailed to your home


Upon receiving your Nerivio, you are welcome to contact the Nerivio Cares Team with any questions Monday-Friday between 8 am and 8 pm ET at 937-637-4846 or support@nerivio.com


Drug-free, easy-to-use, non-invasive wearable device to treat and prevent migraine

Text NERIVIO to 866-637-4846 to receive the Nerivio App.


For assistance activating your device or for any technical questions, contact Nerivio Cares Customer Support at 1-937-NERIVIO (937-637-4846) or support@nerivio.com


Sources
- https://americanmigrainefoundation.org/resource-library/veterans-and-migraine/
- GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-976. doi:10.1016/S1474-4422(18)30322-3
- Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019;59(8): 1240-1252
- Marmura MJ, Lin T, Harris D, lroni A, Rosen NL. Incorporating Remote Electrical Neuromodulation (REN) Into Usual Care Reduces Acute Migraine Medication. Use: An Open-Label Extension Study. Frontiers in Neurology. 2020; 11 :226
- Tepper SJ, et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache. 2023. doi: 10.1111/head.14469.